OBJECTIVES: Quorum sensing (QS)-deficient Pseudomonas aeruginosa biofilms formed in vitro are more susceptible to tobramycin than QS-proficient P. aeruginosa biofilms, and combination treatment with a QS inhibitor (QSI) and tobramycin shows synergistic effects on the killing of in vitro biofilms. We extended these results to an in vivo P. aeruginosa foreign-body biofilm model. The effect of treatment initiated prophylactically was compared with treatment initiated 11 days post-insertion. METHODS: Silicone tube implants pre-colonized with wild-type P. aeruginosa were inserted into the peritoneal cavity of BALB/c mice. Mice were treated with intraperitoneal or subcutaneous injections of the QSIs furanone C-30, ajoene or horseradish juice extract in combination with tobramycin. Mice were euthanized on day 1, 2, 3 or 14 post-infection for the estimation of quantitative bacteriology, histopathology and cytokine measurements. RESULTS: Combination treatment of P. aeruginosa resulted in a significantly lower cfu per implant as compared with the placebo groups for all QSIs tested. For early-initiated treatment, a significant difference in clearing was also observed between the combination group and the single-treatment groups, and between the placebo group and the single-treatment groups. In one case a significant difference in clearing was found between the two single-treatment groups. CONCLUSIONS: Synergistic antimicrobial efficacy could be achieved when treating mice with both a QSI and tobramycin, resulting in an increased clearance of P. aeruginosa in a foreign-body infection model. Our study highlights the important prospects in developing an early combinatory treatment strategy for chronic infections.
OBJECTIVES: Quorum sensing (QS)-deficient Pseudomonas aeruginosa biofilms formed in vitro are more susceptible to tobramycin than QS-proficient P. aeruginosa biofilms, and combination treatment with a QS inhibitor (QSI) and tobramycin shows synergistic effects on the killing of in vitro biofilms. We extended these results to an in vivo P. aeruginosa foreign-body biofilm model. The effect of treatment initiated prophylactically was compared with treatment initiated 11 days post-insertion. METHODS:Silicone tube implants pre-colonized with wild-type P. aeruginosa were inserted into the peritoneal cavity of BALB/c mice. Mice were treated with intraperitoneal or subcutaneous injections of the QSIs furanone C-30, ajoene or horseradish juice extract in combination with tobramycin. Mice were euthanized on day 1, 2, 3 or 14 post-infection for the estimation of quantitative bacteriology, histopathology and cytokine measurements. RESULTS: Combination treatment of P. aeruginosa resulted in a significantly lower cfu per implant as compared with the placebo groups for all QSIs tested. For early-initiated treatment, a significant difference in clearing was also observed between the combination group and the single-treatment groups, and between the placebo group and the single-treatment groups. In one case a significant difference in clearing was found between the two single-treatment groups. CONCLUSIONS: Synergistic antimicrobial efficacy could be achieved when treating mice with both a QSI and tobramycin, resulting in an increased clearance of P. aeruginosa in a foreign-body infection model. Our study highlights the important prospects in developing an early combinatory treatment strategy for chronic infections.
Authors: Tim Holm Jakobsen; Steinn Kristinn Bragason; Richard Kerry Phipps; Louise Dahl Christensen; Maria van Gennip; Morten Alhede; Mette Skindersoe; Thomas Ostenfeld Larsen; Niels Høiby; Thomas Bjarnsholt; Michael Givskov Journal: Appl Environ Microbiol Date: 2012-01-27 Impact factor: 4.792
Authors: Tim Holm Jakobsen; Maria van Gennip; Richard Kerry Phipps; Meenakshi Sundaram Shanmugham; Louise Dahl Christensen; Morten Alhede; Mette Eline Skindersoe; Thomas Bovbjerg Rasmussen; Karlheinz Friedrich; Friedrich Uthe; Peter Østrup Jensen; Claus Moser; Kristian Fog Nielsen; Leo Eberl; Thomas Ostenfeld Larsen; David Tanner; Niels Høiby; Thomas Bjarnsholt; Michael Givskov Journal: Antimicrob Agents Chemother Date: 2012-02-06 Impact factor: 5.191
Authors: Ammar Algburi; Nicole Comito; Dimitri Kashtanov; Leon M T Dicks; Michael L Chikindas Journal: Appl Environ Microbiol Date: 2017-01-17 Impact factor: 4.792
Authors: Carlos J Sanchez; Kevin S Akers; Desiree R Romano; Ronald L Woodbury; Sharanda K Hardy; Clinton K Murray; Joseph C Wenke Journal: Antimicrob Agents Chemother Date: 2014-05-19 Impact factor: 5.191